Cargando…
Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study)
BACKGROUND: Previous randomized-controlled trials have shown that targeting higher hemoglobin (Hb) levels using high dose of ESA in non-dialysis chronic kidney disease (NDCKD) patients resulted in poorer cardiovascular outcome; however, it remains unknown how high Hb levels achieved by ESA in clinic...
Autores principales: | Hayashi, Terumasa, Uemura, Yukari, Kumagai, Michiko, Kimpara, Masashi, Kanno, Hiroyuki, Ohashi, Yasuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394571/ https://www.ncbi.nlm.nih.gov/pubmed/30291472 http://dx.doi.org/10.1007/s10157-018-1649-0 |
Ejemplares similares
-
Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats
por: Hirata, Michinori, et al.
Publicado: (2015) -
Renal Hypoxia in CKD; Pathophysiology and Detecting Methods
por: Hirakawa, Yosuke, et al.
Publicado: (2017) -
Effectiveness of renal sympathetic denervation in renal function and blood pressure in CKD and non-CKD patients with controlled vs. uncontrolled hypertension
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2016) -
Proteomics of CKD progression in the chronic renal insufficiency cohort
por: Dubin, Ruth F., et al.
Publicado: (2023) -
Cancer Treatment in CKD: Time to Move Beyond Renalism
por: Berger, Joseph Rossi, et al.
Publicado: (2023)